Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 12/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 12/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NQO2 | P16083 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740907 | 0.75 | LMNA (0.64) | PDE3BPDE3ALMNAALDH1A1KDM4E | |
| SCHEMBL19146396 | 0.72 | NQO2 (0.60) | PDE3BPDE3ALMNAALDH1A1NQO2 | |
| SCHEMBL16747724 | 0.69 | LMNA (0.72) | PDE3BPDE3ALMNAALDH1A1KDM4E | |
| SCHEMBL31664560 | 0.69 | KDM4E (0.59) | PDE3BPDE3ALMNAALDH1A1NQO2 | |
| SCHEMBL16740939 | 0.69 | PDE3B (1.00) | PDE3BPDE3AALDH1A1KDM4EHPGD | |
| SCHEMBL9984747 | 0.69 | PDE3B (0.51) | PDE3BPDE3AALDH1A1KDM4EHPGD | |
| SCHEMBL16740896 | 0.67 | ALDH1A1 (1.00) | LMNAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL16740903 | 0.67 | PDE3B (0.65) | PDE3BPDE3AALDH1A1KDM4EHPGD | |
| SCHEMBL25903984 | 0.66 | LMNA (0.46) | PDE3BPDE3ALMNAALDH1A1NQO2 | |
| SCHEMBL16740923 | 0.66 | PDE3B (0.74) | PDE3BPDE3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015077193-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077193-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| EP-0252721-B1 | 4-NITROGEN SUBSTITUTED ISOQUINOLINOL COMPOUNDS HAVING CARDIOTONIC, PHOSPHODIESTERASE FRACTION III INHIBITING PROPERTIES AND/OR RENAL VASODILATING PROPERTIES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-10-02 | — | — | EP | disclosed |
| US-4880817-A | O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-11-14 | — | — | US | disclosed |
| CN-87105724-A | Have cardiac stimulant, suppress the different hydroxyquinoline compounds that the 4-nitrogen of the character of phosphodiesterase part III and/or kidney vasorelaxation character replaces | — | 1988-03-09 | — | — | CN | disclosed |
| EP-0252721-A1 | 4-Nitrogen substituted isoquinolinol compounds having cardiotonic, phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-01-13 | — | — | EP | disclosed |
| US-4714705-A | 4-nitrogen substituted isoquinolinol compounds having cardiotonic, phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | EZH2, DOT1L, EHMT1 | PDE3B 3943/4885PDE3A 3977/4885LMNA 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.